Submission	DMF No.	Registration Status
Liraglutide	34104	FA Letter received from US-FDA
Semaglutide	36273	FA Letter received from US-FDA
Tirzepatide	39465	US DMF was submitted in 2024
Eptifibatide	23786	Approved by FDA
Bivalirudin	32281	Approved by FDA
Lanreotide Acetate	29693	Approved by FDA
Octreotide Acetate	29710	Approved by FDA
Fulvestrant	33902	Approved by FDA
Cetrorelix acetate	35171	FA Letter received from US-FDA
Desmopressin Acetate	37799	US DMF was submitted in Dec. 2022
Oseltamivir Phosphate	33907	FA Letter received from US-FDA

Submission	DMF No.	Registration Status
Liraglutide	Y20220000633	Under technical review
Semaglutide	Y20220001086	Under technical review
Octreotide Acetate	Y20180001746	Approved by related authority
Bivalirudin	Y20190000290	Approved by related authority
Eptifibatide	Y20180001360	Approved by related authority
Fulvestrant	Y20200001489	Approved by related authority
Alagliptin benzoate	Y20180000506	Approved by related authority
Oseltamivir Phosphate	Y20200000736	Approved by related authority
Albuvirtide	Y20200001298	Approved by related authority
Thymalfasin	Y20170001373	Approved by related authority
Desmopressin Acetate	Y20220001250	Under technical review
Cetrorelix acetate	Y20220000567	Under technical review
Epalrestat	Y20220001175	Under technical review
Atorvastatin calcium	Y20210001031	Under technical review
Sodium Picosulfate	Y20220000698	Under technical review